Gpc3 expression correlates with the phenotype of the Simpson-Golabi-Behmel syndrome
β Scribed by Massimo Pellegrini; Giuseppe Pilia; Serafino Pantano; Franco Lucchini; Manuela Uda; Mariapaola Fumi; Antonio Cao; David Schlessinger; Antonino Forabosco
- Publisher
- John Wiley and Sons
- Year
- 1998
- Tongue
- English
- Weight
- 711 KB
- Volume
- 213
- Category
- Article
- ISSN
- 1058-8388
No coin nor oath required. For personal study only.
β¦ Synopsis
Interest in glypican-3 (GPC3), a member of the glypican-related integral membrane heparan sulfate proteoglycans (GRIPS) family, has increased with the finding that it is mutated in the Simpson-Golabi-Behmel overgrowth syndrome (Pilia et al. [1996] Nat. Genet. 12:241-247). The working model suggested that the membrane-bound protein acts locally to limit tissue and organ growth and that it may function by interacting with insulin-like growth factor 2 (IGF2) to limit its local effective level. Here we have tested two predictions of the model. In situ hybridization with the mouse gene cDNA was used to study the expression pattern during embryonic and fetal development. In agreement with predictions, the gene is expressed in precisely the organs that overgrow in its absence; and the patterns of expression of Gpc3 and those reported for Igf 2 are strictly correlated.
π SIMILAR VOLUMES
Simpson-Golabi-Behmel syndrome (SGBS) is an X-linked overgrowth syndrome caused by deletions in glypican 3 (GPC3). SGBS is characterized by pre- and postnatal overgrowth, a characteristic facial appearance, and a spectrum of congenital malformations which overlaps that of other overgrowth syndromes.
The Simpson-Golabi-Behmel syndrome (SGBS) is an overgrowth/multiple congenital anomalies/dysplasia syndrome caused by a mutant X-linked gene. The spectrum of its clinical manifestations is broad, varying from very mild forms in carrier females to infantile lethal forms in affected males. A typically